Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism

Cardiovasc Res. 2013 Jan 1;97(1):23-32. doi: 10.1093/cvr/cvs296. Epub 2012 Sep 20.

Abstract

Aims: Several drugs blocking the rapidly activating potassium (K(r)) channel cause malformations (including cardiac defects) and embryonic death in animal teratology studies. In humans, these drugs have an established risk for acquired long-QT syndrome and arrhythmia. Recently, associations between cardiac defects and spontaneous abortions have been reported for drugs widely used in pregnancy (e.g. antidepressants), with long-QT syndrome risk. To investigate whether a common embryonic adverse-effect mechanism exists in the human, rat, and rabbit embryos, we made a comparative study of embryonic cardiomyocytes from all three species.

Methods and results: Patch-clamp and quantitative-mRNA measurements of K(r) and slowly activating K (K(s)) channels were performed on human, rat, and rabbit primary cardiomyocytes and cardiac samples from different embryo-foetal stages. The K(r) channel was present when the heart started to beat in all species, but was, in contrast to human and rabbit, lost in rats in late organogenesis. The specific K(r)-channel blocker E-4031 prolonged the action potential in a species- and development-dependent fashion, consistent with the observed K(r)-channel expression pattern and reported sensitive periods of developmental toxicity. E-4031 also increased the QT interval and induced 2:1 atrio-ventricular block in multi-electrode array electrographic recordings of rat embryos. The K(s) channel was expressed in human and rat throughout the embryo-foetal period but not in rabbit.

Conclusion: This first comparison of mRNA expression, potassium currents, and action-potential characteristics, with and without a specific K(r)-channel blocker in human, rat, and rabbit embryos provides evidence of K(r)-channel inhibition as a common mechanism for embryonic malformations and death.

Publication types

  • Comparative Study

MeSH terms

  • Action Potentials
  • Animals
  • Atrioventricular Block / chemically induced
  • Atrioventricular Block / metabolism
  • Cells, Cultured
  • ERG1 Potassium Channel
  • Electrocardiography
  • Ether-A-Go-Go Potassium Channels / antagonists & inhibitors
  • Ether-A-Go-Go Potassium Channels / metabolism
  • Gene Expression Regulation, Developmental
  • Gestational Age
  • Heart Defects, Congenital / chemically induced*
  • Heart Defects, Congenital / genetics
  • Heart Defects, Congenital / metabolism
  • Humans
  • KCNQ1 Potassium Channel / antagonists & inhibitors
  • KCNQ1 Potassium Channel / metabolism
  • Kinetics
  • Long QT Syndrome / chemically induced
  • Long QT Syndrome / metabolism
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Organogenesis
  • Patch-Clamp Techniques
  • Piperidines / toxicity*
  • Polymerase Chain Reaction
  • Potassium Channel Blockers / toxicity*
  • Potassium Channels, Voltage-Gated / antagonists & inhibitors*
  • Potassium Channels, Voltage-Gated / genetics
  • Potassium Channels, Voltage-Gated / metabolism
  • Pyridines / toxicity*
  • RNA, Messenger / metabolism
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Wistar
  • Species Specificity
  • Teratogens / toxicity*

Substances

  • ERG1 Potassium Channel
  • Ether-A-Go-Go Potassium Channels
  • KCNE1 protein, human
  • KCNE2 protein, human
  • KCNE2 protein, rat
  • KCNQ1 Potassium Channel
  • KCNQ1 protein, human
  • Kcne1 protein, rat
  • Kcnq1 protein, rat
  • Piperidines
  • Potassium Channel Blockers
  • Potassium Channels, Voltage-Gated
  • Pyridines
  • RNA, Messenger
  • Teratogens
  • E 4031